Epilogue: New Drugs for Neglected Diseases

&
Cambridge Quarterly of Healthcare Ethics 20 (2):329-334 (2011)
  Copy   BIBTEX

Abstract

In a widely cited 2003 article, DiMasi, Hansen, and Grabowski estimated the cost of pharmaceutical research and development to be $1.1 billion per new medicine coming onto the market in 2001. They also estimate that this cost is going up at a real rate of 7.4% annually. According to these estimates, the innovation cost per new medicine today is about $2.1 billion or $2.65 billion

Categories

Keywords

Reprint years

DOI

10.1017/s0963180110000988

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,164

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Advance Monopoly Commitment?J. Sonderholm - 2011 - Public Health Ethics 4 (3):297-302.
In defence of priority review vouchers.Jorn Sonderholm - 2009 - Bioethics 23 (7):413-420.
Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases.J. Sonderholm - 2009 - Journal of Medical Ethics 35 (5):315-319.
Measuring Global Health Impact: Incentivizing Research and Development of Drugs for Neglected Diseases.Nicole Hassoun - 2012 - Developing World Bioethics 12 (3):121-134.
A Reform Proposal in Need of Reform: A Critique of Thomas Pogge's Proposal for How to Incentivize Research and Development of Essential Drugs.J. Sonderholm - 2010 - Public Health Ethics 3 (2):167-177.
Ethical and social aspects on rare diseases.Dusanka Krajnovic - 2012 - Filozofija I Društvo 23 (4):32-48.
A theoretical flaw in the advance market commitment idea.J. Sonderholm - 2010 - Journal of Medical Ethics 36 (6):339-343.
Ethical issues in funding research and development of drugs for neglected tropical diseases.L. Oprea, A. Braunack-Mayer & C. A. Gericke - 2009 - Journal of Medical Ethics 35 (5):310-314.
Defining Neglected Disease.Alex Broadbent - 2011 - Biosocieties 6 (1):51-70.
Biomedical Research, Neglected Diseases, and Well-Ordered Science.Philip Kitcher - 2009 - Theoria: Revista de Teoría, Historia y Fundamentos de la Ciencia 24 (3):263-282.
Epilogue: What good are drugs anyway?Lester H. Hunt - 2003 - Criminal Justice Ethics 22 (1):46-49.
Effective use of a limited antiviral stockpile for pandemic influenza.Nimalan Arinaminpathy, J. Savulescu & Angela R. Mclean - 2009 - Journal of Bioethical Inquiry 6 (2):171-179.
Biomedical research, neglected diseases, and well-ordered science.Julian Reiss & Philip Kitcher - 2009 - Theoria: Revista de Teoría, Historia y Fundamentos de la Ciencia 24 (3):263-282.
Human rights and global health: A research program.Thomas W. Pogge - 2005 - Metaphilosophy 36 (1‐2):182-209.
Strategic Corporate Social Responsibility and Orphan Drug Development: Insights from the US and the EU Biopharmaceutical Industry. [REVIEW]Olga Bruyaka, Hanko K. Zeitzmann, Isabelle Chalamon, Richard E. Wokutch & Pooja Thakur - 2013 - Journal of Business Ethics 117 (1):45-65.

Analytics

Added to PP
2013-12-09

Downloads
39 (#386,963)

6 months
2 (#1,136,865)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Thomas W. Pogge
Yale University

Citations of this work

No citations found.

Add more citations

References found in this work

Access to Healthcare and the Pharmaceutical Sector.Klaus M. Leisinger & Karin M. Schmitt - 2011 - Cambridge Quarterly of Healthcare Ethics 20 (2):309-325.

View all 6 references / Add more references